Samsung Electronics Co., Ltd.

Korea Institute of Science and Technology

Seung Ja Oh

Ji Min Lee

Kyung Eun Kim

Sang Yeul Han

Hyo Seon Lee

Bo Gyou Kim

Kyung Ah Kim

Sang-Heon Kim

Seung Hyun Lee

Joo Young Lee

Hyun Kwang Seok

Soo Yeon Jung

Yu Chan Kim

Jae Woong Hwang

Sang Heon Kim

Saet Byoul Lee

Myoung-Ryul Ok

Hojeong Jeon

Hyunseon Seo

Kwi Deok Park

Youngmin Seo

Ha Eun Chung

Seokheon Hong

Provided is a method of preparing a three-dimensional cell spheroid, the method including forming the cell spheroid by co-culturing adipose-derived stem cells or mesenchymal stem cells with hepatocytes. According to the cell spheroid prepared by the method, the secretome secreted by the adipose-derived stem cells affects hepatocyte maturation, and therefore, hepatic functions of the finally formed three-dimensional cell spheroid, i.e., organoid, may be enhanced. Further, a composition including a culture medium of the adipose-derived stem cells may prevent or treat liver diseases including hepatitis, hepatotoxicity, cholestasis, fatty liver, etc., and may enhance hepatic functions.

Method of preparing three-dimensional cell spheroid including adipose-derived stem cells and hepatocytes

The present disclosure relates to a microgel composition comprising collagen and hyaluronic acid and a method of preparing the same. The microgel according to an embodiment is composed of natural biocompatible substances and is non-toxic and has high mechanical stability or long persistence, and thus can be effectively used in a microgel composition, a three-dimensional scaffold composition, and a tissue-engineering scaffold.

Microgel composition comprising collagen and method of preparing the same

Provided is a method for the selective differentiation into M1 macrophages under a pressurized environment, and more particularly, a method for the selective differentiation of undifferentiated macrophages into M1 macrophages, the method including incubating the undifferentiated macrophages in an incubator under the pressurized environment. In addition, provided is a method for producing osteoclasts, the method including: incubating undifferentiated macrophages in an incubator under a pressurized environment to differentiate into M1 macrophages; and differentiating the differentiated M1 macrophages into osteoclasts.

Method of selectively differentiating undifferentiated macrophage into M1 macrophage

Provided are a hydrogel composition with high viscoelasticity and a bioink composition including the hydrogel composition. The hydrogel composition according to an embodiment is composed of natural biocompatible substances and thus is not toxic, but has high viscosity, resulting in high mechanical stability or long persistence. Thus, the hydrogel composition may be usefully utilized as a bioink composition for bioprinting, a support in tissue engineering, or a soft tissue filler.

Hydrogel composition and bioink composition including the same

An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.

Anti-ANG2 antibody

A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.

Biomarker PNCK for predicting effect of a dual-targeting agent

A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.

Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same

A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

Biomarker Hsp90 for predicting effect of a c-Met inhibitor

A method for the prevention and/or treatment of a disease accompanied by vascular leakage and/or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.

Growing community of inventors

Seoul, South Korea

Seung Ja Oh